Due tonational shortageof the nebulization solutions, theformulary status of inhaler products has been temporarily adjusted to formulary, restricted to use during the albuterol/Duoneb shortage. Upon shortage resolution, these products willautomatically return to their original formulary status. SeeAlbuterol/Duoneb Shortage Mitigationfor more information. (UpdatedFeb 2023)
ORDERED FORMULATION
THERAPEUTIC INTERCHANGE
NOTES
tiotropium-olodaterol (Stiolto Respimat)
3.124 mcg tiotropium and 2.736 mcg olodaterol per activation TWO puffs once Daily
Due to national shortage of the nebulization solutions, the formulary status of inhaler products has been temporarily adjusted to formulary, restricted to use during the albuterol/Duoneb shortage. Upon shortage resolution, these products will automatically return to their original formulary status. See Albuterol/Duoneb Shortage Mitigation for more information. (Updated Feb 2023)
ORDERED FORMULATION
THERAPEUTIC INTERCHANGE
NOTES
tiotropium-olodaterol (Stiolto Respimat)
albuterol-ipratropium (DuoNeb)
Stiolto Respimat is non-formulary, not stocked. Do not exceed 6 DuoNeb vials in 24 hours.
Stiolto Respimat medication guide
Reviewed: 28 October 2015 (Stiolto Respimat)